AKAP8L

Across TCGA pan-cancer cohorts, AKAP8L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AKAP8L data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AKAP8L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKAP8L expression acts as an unfavorable survival marker.

BLCA, LUAD, and COAD are the cancer types where AKAP8L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.170	0.574	.011	12	view →
LUAD	DFS	Median	All	0.245	0.667	.002	12	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AKAP8L–BLCA (DFS)

Open the BLCA breakdown →